Biote

Biote Free Cash Flow

The Free Cash Flow (FCF) of Biote (BTMD) as of Nov 21, 2026 is 30.18 M USD. In the previous year, Free Cash Flow (FCF) was 38.81 M USD — a change of -22.25% (lower).

Free Cash Flow

30.18 MUSD

YoY

-22.25%

Last updated:

Free Cash Flow (FCF) of Biote is 2025 30.18 M USD. Free Cash Flow (FCF) of Biote was 2024 38.81 M USD. It decreases by -22.25% lower compared to the previous year.

The Biote Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2019
23.68 M USD
Jan 1, 2020
25.03 M USD
Jan 1, 2021
29.91 M USD
Jan 1, 2022
-11.00 M USD
Jan 1, 2023
24.17 M USD
Jan 1, 2024
38.81 M USD
Jan 1, 2025
30.18 M USD
The Biote Free Cash Flow history
YEARFree Cash FlowYoY
30.18 MUSD-22.25%
38.81 MUSD+60.58%
24.17 MUSD-319.83%
-11.00 MUSD-136.76%
29.91 MUSD+19.50%
25.03 MUSD+5.70%
23.68 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

Free Cash Flow (FCF) of Biote is 30.18 M USD in 2025.

Free Cash Flow (FCF) of Biote changed from 38.81 M USD to 30.18 M USD, representing a -22.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Biote since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Biote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biote

All Key Metrics — Biote